China National Pharmaceutical Group Corporation

Compared with placebo, the analgesic effect of a small dose of Nasotong nasal spray (1 spray/headache attack) in the treatment of acute migraine (blood stasis syndrome) was preliminarily evaluated. At the same time, the local tolerance and safety of the product were observed to provide a design basis for the next clinical trial.

The clinical positioning of the Naotong nasal spray is rapid analgesia. The purpose of this clinical trial is to formulate a dosing regimen based on the local tolerance clinical trial of the Naotong nasal spray in humans and the preliminary exploratory trial of Phase IIa, to further evaluate the effectiveness and safety of the Naotong nasal spray in the acute stage of migraine (blood stasis syndrome), and to provide a design basis for the next clinical trial.

Select voluntary subjects with normal nasal mucosa to observe the local tolerance of the nasal-brain universal spray and the local changes in the nasal cavity after medication, including the effect of this product on the nasal mucosa, to provide safety information for this product and provide a design basis for the next clinical trial.